PRESSEPORTAL Presseportal Logo
All Stories
Subscribe to Norgine

23.02.2018 – 14:01


UK High Court of Justice Rules Endocuff® and Endocuff Vision® Patents and Design Rights to be Valid and Infringed

AmsterdamAmsterdam (ots/PRNewswire)

Arc Medical Design Limited, a subsidiary of Norgine B.V., today announced that the High Court of Justice England and Wales, Patents Court ruled that ENDOCUFF® and ENDOCUFF VISION® UK national and UK(EP) patents (as amended) are valid and infringed by Cantel's AmplifEYE® endoscopic device, and key design rights are valid and infringed by AmplifEYE®. The patent and design rights had been challenged by Cantel Medical (UK) Limited and Cantel (UK) Limited.

(Logo: )

Peter Martin, COO of Norgine and Chair of the Arc Medical Design Limited Board said: "We welcome the judgement and our resounding success, recognising the strong protection for both ENDOCUFF® and ENDOCUFF VISION®. This decision validates our confidence in the intellectual property portfolio protecting our products. We will always vigorously defend our intellectual property and will initiate legal proceedings where appropriate."

ENDOCUFF VISION® is a single use device attached at the end of the colonoscope that gives an optimal view of the entire colon by retracting folds during withdrawal.

Notes to Editors:

About the UK Case No. HP-2016-000047

On Friday 23 February 2018 the High Court of Justice England and Wales, Patents Court ruled that:Arc Medical Design Limited won on all counts:

- Arc Medical Design Limited's ENDOCUFF and ENDOCUFF VISION UK 
  national patent 2478081 and UK(EP) patent 2575590, as amended, are 
  valid and infringed;
- its ENDOCUFF VISION Registered Community Design 002523191-0001 is 
  valid and infringed, its ENDOCUFF Registered Community Design 
  001856121-0001 is valid but not infringed; and
- its UK unregistered design rights in ENDOCUFF and ENDOCUFF VISION 
  will be infringed from the date of the judgment.
- The judgment is for the UK market. 

View the full media release on

Media Contact:

Isabelle Jouin, T: +44 (0)1895 453643

Follow us @norgine

Original content of: Norgine, transmitted by news aktuell

More stories: Norgine
More stories: Norgine